Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Epigenomics AG (EPGNF) - Total Liabilities
Latest total liabilities as of June 2025: $11.86 Million USD
Based on the latest financial reports, Epigenomics AG (EPGNF) has total liabilities worth $11.86 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Epigenomics AG - Total Liabilities Trend (2003–2024)
This chart illustrates how Epigenomics AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Epigenomics AG Competitors by Total Liabilities
The table below lists competitors of Epigenomics AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vienna International Airport
STU:FLW1
|
Germany | €672.20 Million |
|
BEACN Wizardry & Magic Inc
V:BECN
|
Canada | CA$1.67 Million |
|
TELEPERFORMANCE - Dusseldorf Stock Exchang
DU:RCF
|
Germany | €7.52 Billion |
|
Dowa Holdings Co. Ltd
DU:DMI
|
Germany | €243.98 Billion |
|
Xali Gold Corp
PINK:CGDXF
|
USA | $3.44 Million |
|
NGS Group AB (publ)
ST:NGS
|
Sweden | Skr53.24 Million |
|
SKYWORKS SOLUTIONS (AWM.SG)
STU:AWM
|
Germany | €1.95 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Epigenomics AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | N/A | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Epigenomics AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Epigenomics AG (2003–2024)
The table below shows the annual total liabilities of Epigenomics AG from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $12.27 Million | -41.18% |
| 2023-12-31 | $20.86 Million | +267.26% |
| 2022-12-31 | $5.68 Million | +123.36% |
| 2021-12-31 | $2.54 Million | -13.30% |
| 2020-12-31 | $2.93 Million | -32.73% |
| 2019-12-31 | $4.36 Million | +35.66% |
| 2018-12-31 | $3.21 Million | -65.05% |
| 2017-12-31 | $9.20 Million | +142.13% |
| 2016-12-31 | $3.80 Million | -30.95% |
| 2015-12-31 | $5.50 Million | +5.53% |
| 2014-12-31 | $5.21 Million | +12.77% |
| 2013-12-31 | $4.62 Million | +69.93% |
| 2012-12-31 | $2.72 Million | -17.00% |
| 2011-12-31 | $3.28 Million | +28.86% |
| 2010-12-31 | $2.54 Million | -40.44% |
| 2009-12-31 | $4.27 Million | +14.94% |
| 2008-12-31 | $3.71 Million | -27.06% |
| 2007-12-31 | $5.09 Million | +204.24% |
| 2006-12-31 | $1.67 Million | -70.22% |
| 2005-12-31 | $5.62 Million | +1.39% |
| 2004-12-31 | $5.54 Million | -59.21% |
| 2003-12-31 | $13.59 Million | -- |